Analyst consensus rating
Chemomab Therapeutics Analyst Rating: none
Direct answer
Chemomab Therapeutics's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.00.
Forecast evidence checked November 13, 2026.
Get free Chemomab Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.40
- Average price target
- $5.00
- High price target
- $5.00
- Low price target
- $5.00
- Low target gap
- +257.1%
- Target upside
- +257.1%
- High target gap
- +257.1%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Chemomab Therapeutics?
Chemomab Therapeutics has a verified none consensus. The same dataset has an average price target of $5.00.
How far are Chemomab Therapeutics's low and high targets from the recorded price?
The low target implies +257.1%, while the high target implies +257.1%.
How many analysts are included in Chemomab Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Chemomab Therapeutics's target upside or downside calculated?
The average target of $5.00 is divided by the recorded price of $1.40, then one is subtracted to produce +257.1%. This does not guarantee a future return.
When was Chemomab Therapeutics's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.